Key takeaways
Duobrii (halobetasol/tazarotene) and Tremfya (guselkumab) are both used to treat plaque psoriasis, but they work in different ways and are used for different severities of the condition. Duobrii is a topical lotion that combines a corticosteroid and a retinoid to reduce inflammation and alter skin cell growth. It's applied once daily and is only available as a brand-name medication. On the other hand, Tremfya is an injection that targets a specific protein interleukin-23 (IL-23) to lower inflammation and is used for moderate-to-severe plaque psoriasis, ulcerative colitis, and psoriatic arthritis. Tremfya is also a brand-name medication and is injected every 8 weeks after initial doses. Duobrii can cause skin sensitivity to the sun and isn't recommended for long-term use, while Tremfya can raise the risk of infections and requires monitoring for tuberculosis. Additionally, Duobrii is not safe for use during pregnancy, whereas the safety of Tremfya during pregnancy is not well established.
